Cardiovascular news covering heart disease, stroke, blood pressure, cholesterol, and cardiac treatment advances.
Dr. Daniel W. Jones argues that the American Heart Association's new blood pressure target of 130/80 significantly expands the population eligible for medication, citing evidence linking tighter control to reduced dementia risk and improved cardiovascular outcomes.
The Indian Express argues that natural remedies cannot remove existing arterial plaque, citing cardiologist Dr. Punya Pratap. The article contends that while lifestyle changes like diet and exercise stabilize plaque and slow progression, medical treatment remains necessary for established atherosclerosis.
Florida high school student Cameron Crider was diagnosed with an asymptomatic atrial septal defect after mandatory ECG screenings under the state's Second Chance Act. Crider, who plays football and basketball, is scheduled for corrective surgery in October despite having no prior symptoms.
A comprehensive review in Nature Reviews Cardiology identifies a cardiovascular continuum of harm across all nicotine delivery methods. Lead author Thomas Münzel states that while removing combustion reduces risk, eliminating nicotine entirely is the only way to remove cardiovascular danger.
Dr. Keith Roach addresses reader inquiries regarding hydralazine supply issues for hypertension and the transmission mechanics of Legionnaires' disease. He suggests consulting a physician for substitutes and clarifies that Legionella spreads via aerosolized water from environmental sources rather than person-to-person contact.
The authors argue that the MIST trial redefines contemporary coronary surgery by validating minimally invasive cardiac surgery (MICS) CABG. They contend that despite historical concerns about revascularization quality, the trial demonstrates that smaller incisions can achieve durability and survival benefits comparable to conventional median sternotomy.
A phase 2 study at Nanjing Drum Tower Hospital reports that 90% of heart failure patients treated with induced pluripotent stem cell-derived heart muscle cells showed significant cardiac recovery. The trial, involving 10 treated and 10 control patients, found no severe adverse events and noted greater improvements in walking distance for the treatment group over a 12-month period.
The authors respond to correspondence regarding their recent study on long-term antiplatelet therapy after percutaneous coronary intervention. They argue that the raised points concerning secondary prevention are fundamental and merit further elaboration to clarify clinical implications.
The commentary argues that ten-year HOST-EXAM trial data challenges aspirin's primacy in chronic secondary prevention after percutaneous coronary intervention. It contends clopidogrel monotherapy offers sustained reductions in ischaemic and bleeding outcomes without mortality signals, supported by meta-analyses.
Cardiologist Dr. Jeremy London argues that consistent daily habits, particularly sleep and oral hygiene, outweigh supplements and trends for cardiovascular health. The commentary suggests prioritizing sleep, exercise, and dental care over red wine or CoQ10 to ensure long-term heart well-being.